Document resource
Objectives Case series in patients treated with CAR-T cells have suggested that a deep state of remission, characterized by clinical and serological quiescence, the absence of a need for treatment, and a long duration is attainable for at least some patients with SLE. The degree to which this occurs in the global patient population and under which circumstances is unclear.Our objectives are to determine, in a large global patient population, the prevalence of, and predictors for, long-lasting ‘deep’ remission in SLE.Methods The SLE international collaborating clinics (SLICC) group is a 42-member international consortium dedicated to registry- or cohort-based studies of lupus. Through a series of on-line meetings and discussion at the most recent global live meetings the consortium has come to an agreement on the current study.Results The protocol for the ‘LOREL’ study has now been agreed upon. Thus, all participating sites will analyze the prevalence of, and predictors for, long-lasting remission in their cohorts or registries. They will study all patients known to the registry on the index and collect a set of narrowly defined demographic, disease and treatment characteristics available in at least 80% of the sites. These data will be assessed retrospectively from the index date. Subsequently, the determination will be made whether the patient during the following ten years achieved a remission according to the DORIS criteria that lasted at least 2 years AND was maintained in the absence of treatment with glucocorticoids and immunosuppressives. Associations between the baseline characteristics and the likelihood of achieving ‘deep’ remission will be analyzed at each site using the same statistical code. The results of these analyses, but not the individual patient-level data, will then be combined using meta-analysis methodology.Abstract LBA:01:20 Table 1Key elements of the LOREL study protocolConclusions The SLICC group has now embarked on the LOREL project with a well-described protocol that leverages the large global patient base of that group. The results of the pooled analyses will clarify the degree to which a deep, long-lasting remission is seen in patients with lupus, the disease characteristics associated with it, and which hitherto available treatments provided the greatest likelihood of achieving this highly favorable outcome.